Physician profile
Eric H Yan
NPI 1225115892
$1,217.42
in general payments reported to CMS, 2019-2025
19 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $138 · 2021: $102 · 2022: $64.44 · 2023: $331 · 2024: $305 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695 · Education: $82.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.56 |
| Education | $82.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $390.90 | 2022-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $126.38 | 2019-2021 | |
| Nxstage Medical, INC. | $100.32 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.41 | 2019-2020 | |
| Travere Therapeutics, INC. | $69.18 | 2023-2025 | Filspari |
| Amgen INC. | $57.56 | 2019-2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $53.91 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.34 | 2023-2025 | Jardiance, Tradjenta |
| Medtronic, INC. | $51.03 | 2025 | Symplicity G3 |
| Ardelyx, INC. | $40.48 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $40.21 | 2024-2025 | Ozempic |
| Mallinckrodt Enterprises LLC | $27.38 | 2019 | |
| Akebia Therapeutics INC | $21.59 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.85 | 2021 | |
| Daiichi Sankyo INC. | $16.55 | 2023 | Injectafer |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.66 | 2024 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.